DeepMed Research

Sintilimab

Generic Name: Sintilimab

Drug Type: Biotech

CAS Number: 2072873-06-2

Unique Ingredient Identifier: 8FU7FQ8UPK

Clinical Trials

A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis

Phase 2

Not yet recruiting

Conditions: Stomach Neoplasms

Interventions: Drug: Sintilimab
Drug: Ramucirumab
Drug: SOX/XELOX

First Posted Date: 2024-08-21

Last Posted Date: 2024-08-28

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 39

Registration Number: NCT06564298

Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Biological: Sintilimab
Biological: ZG005 for Injection
Biological: Bevacizumab

First Posted Date: 2024-08-16

Last Posted Date: 2024-12-16

Lead Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Target Recruit Count: 90

Registration Number: NCT06558227

Locations: 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China

A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer

Phase 2

Recruiting

Conditions: Gastric Cancer

Interventions: Drug: Sintilimab
Drug: S-1
Drug: Capecitabine
Radiation: Extraperitoneal radiation therapy

First Posted Date: 2024-08-15

Last Posted Date: 2024-08-15

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 40

Registration Number: NCT06555471

Locations: 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China

PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer

Not Applicable

Not yet recruiting

Conditions: Mismatch Repair Deficiency
Endometrioid Carcinoma
Endometrial Cancer

Interventions: Drug: Sintilimab or Pembrolizumab and medroxyprogesterone acetate (MPA)/ megestrol acetate (MA)

First Posted Date: 2024-08-12

Last Posted Date: 2024-08-12

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 10

Registration Number: NCT06549855

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer

Phase 2

Recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Fruquintinib or Regorafenib
Drug: Sintilimab
Drug: Fruquintinib

First Posted Date: 2024-08-09

Last Posted Date: 2024-08-09

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 68

Registration Number: NCT06543836

Locations: 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

A Phase Ib/II Study of AK112 (PD-1/VEGF Bispecific Antibody) in Combination Therapy for Patients With Advanced Hepatocellular Carcinoma (HCC).

Phase 1

Not yet recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: AK112
Drug: Sintilimab Injection
Drug: AK130
Drug: AK127
Drug: Bevacizumab biosimilar
Drug: Cadonilimab

First Posted Date: 2024-07-31

Last Posted Date: 2024-07-31

Lead Sponsor: Akeso

Target Recruit Count: 280

Registration Number: NCT06530251

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳
Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute,Shandong Cancer Hospital), Jinan, Shandong, China

Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy

Phase 2

Not yet recruiting

Conditions: Renal Cell Carcinoma
Immunotherapy
Molecular Targeted Therapy

Interventions: Drug: Vorolanib Tablets
Drug: Sintilimab Injection

First Posted Date: 2024-07-26

Last Posted Date: 2024-07-26

Lead Sponsor: Hao Zeng

Target Recruit Count: 67

Registration Number: NCT06523049

Locations: 🇨🇳
West China Hospital, Chengdu, Sichuan, China

Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma

Phase 2

Not yet recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Donafenib
Drug: Sintilimab
Other: HAIC

First Posted Date: 2024-07-22

Last Posted Date: 2024-07-22

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT06512467

A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer

Not Applicable

Recruiting

Conditions: NSCLC, Stage IV
NSCLC, Stage III

Interventions: Drug: Leuprorelin acetate + Sintilimab
Drug: Sintilimab

First Posted Date: 2024-07-22

Last Posted Date: 2024-07-22

Lead Sponsor: Jinzhou Medical University

Target Recruit Count: 80

Registration Number: NCT06512207

Locations: 🇨🇳
The Third Oncology Ward, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

Phase 3

Recruiting

Conditions: Colorectal Cancer

Interventions: Drug: Tucidinostat
Drug: Fruquintinib
Drug: Sintilimab
Drug: Bevacizumab

First Posted Date: 2024-07-12

Last Posted Date: 2024-12-03

Lead Sponsor: Chipscreen Biosciences, Ltd.

Target Recruit Count: 430

Registration Number: NCT06497985

Locations: 🇨🇳
Rui-Hua Xu, Guangzhou, Guangdong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy